|
⚲
|
| Exact Sciences Corp | |
|---|---|
| Ticker | EXAS |
| CIK # | 0001124140 |
| CUSIP | 30063P105 |
| Sector | Trade & Services |
| Industry | Services-Commercial Physical & Biological Research |
| Phone | 6082845700 |
| Address | 441 Charmany Drive Madison, WI 53719 |
| Source | [EDGAR] |
| Market Cap, 13F ($) |
|---|
| Business |
|---|
|
Exact Sciences Corporation (together with its subsidiaries, "Exact," "we," "us," "our" or the "Company") is a leading global cancer diagnostics company. We have developed some of the most impactful brands in cancer diagnostics, and we are currently working on the development of additional tests for other types of cancer, with the goal of bringing new innovative cancer tests to patients throughout the world. On November 8, 2019, we completed the acquisition of Genomic Health, Inc. ("Genomic Health"), a leading provider of genomic-based diagnostic tests that help to optimize cancer care, and its Oncotype IQ® Genomic Intelligence Platform comprised of its flagship line of Oncotype DX® gene expression tests. Colorectal cancer is the second leading cause of cancer deaths in the United States ("U.S.") and the leading cause of cancer deaths in the U.S. among non-smokers. Each year in the U.S. there are approximately: |
| CIK | Filing | 2011 - 2023 |
|---|---|---|
| [0001124140] | 10-K | |
| [0001124140] | 10-Q | |
| [0001124140] | 3 | |
| [0001124140] | 4 | |
| [0001124140] | 5 | |
| [0001124140] | 8-K | |
| [0001124140] | SC 13D | |
| [0001124140] | SC 13G |